SCHEDULE: ADAR1 Capital Management Exits Ovid Therapeutics Stake

ADAR1 Capital Management, LLC, along with related entities and individuals, has filed a Schedule 13G amendment indicating a reduction in their beneficial ownership of Ovid Therapeutics Inc. common stock to below 5%.

Summary

• ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger have filed an amendment to their Schedule 13G, indicating an exit from their significant beneficial ownership position in Ovid Therapeutics Inc.
• The filing reports that ADAR1 Capital Management, LLC no longer beneficially owns more than 5% of Ovid Therapeutics Inc. common stock.
• ADAR1 Capital Management GP, LLC is filing this as an exit filing.
• The total number of shares beneficially owned by ADAR1 Capital Management, LLC, including shares held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and separately managed accounts, as well as shares underlying warrants, has decreased.
• The filing is based on 184,755,735 shares of Ovid Therapeutics Inc. common stock outstanding as of June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, primarily due to the indication of an exit by a significant shareholder, which could signal a lack of confidence or a strategic shift away from the company.

Negatives

• ADAR1 Capital Management GP, LLC is filing this as an exit filing, suggesting a complete divestment or significant reduction of their stake.
• The reduction in beneficial ownership by a significant investment manager could be interpreted as a lack of confidence in the company's future prospects or a strategic reallocation of capital.

Risks

• The exit of a significant shareholder like ADAR1 Capital Management could lead to increased share price volatility.
• A substantial sell-off by ADAR1 could put downward pressure on Ovid Therapeutics' stock price.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Ovid Therapeutics Inc. It solely reports on the change in beneficial ownership by ADAR1 Capital Management.

Management Comments

• Mr. Schneeberger certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant shifts in beneficial ownership, particularly an exit by an investment manager, can be a strong signal to the market. This event for Ovid Therapeutics Inc. occurs within a biotech sector that is often characterized by high volatility and dependence on clinical trial results and regulatory approvals.

Stakeholder Impact

• Shareholders may experience increased volatility in Ovid Therapeutics Inc.'s stock price due to the significant shareholder's exit.
• Potential investors may view the exit as a negative signal, potentially impacting future investment decisions.

Next Steps

• ADAR1 Capital Management GP, LLC has completed its exit filing.
• Market participants will likely monitor Ovid Therapeutics Inc. for further developments and performance updates.

Key Dates

Recommendation

The filing indicates a significant shareholder's exit, which is a negative signal. However, without specific financial performance data or strategic updates from Ovid Therapeutics Inc. within this filing, a 'hold' recommendation is prudent. Investors should await further company disclosures or performance metrics before making a more definitive decision.

Keywords

Ovid Therapeutics, Schedule 13G, Beneficial Ownership, Investment Management, Shareholder Exit, Securities Exchange Act